AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Go Back to All Clinical Trials

AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Low Risk And Standard Risk Pediatric And Adult Patients With Germ Cell Tumors
Age: Between 1 years - 99 years
Gender: Male or Female

Other Inclusion Criteria:
1. Patients must have a performance status corresponding to ECOG scores of 0, 1, 2 or 3.
2. Adequate renal function, liver, and hematological function.
3. Patients must have had no prior radiation therapy with the exception of CNS irradiation of brain metastases.

You may not be eligible for this study if the following are true:

1. Patients with significant, pre-existing co-morbid respiratory disease that contraindicate the use of bleomycin.
2. Patients have had systematic therapy for the current cancer diagnosis.
3. Pregnancy and Breast Feeding ( only apply to patients who will receive chemotherapy).

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies